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ABSTRACT OF DISSERTATION
PROGRESSIVE ENDOSCOPIC APPROACH TO BALLOON DILATION FOR
BENIGN ESOPHAGEAL STRICTURES
Benign esophageal strictures are a frequently encountered problem in clinical
practice. The management of benign esophageal strictures have slowly evolved over the
decades based on “expert opinion.” Despite vast amounts of data about the efficacy and
safety of dilation, unfortunately there is no consensus on a systematic and safe approach
that is efficient, limits complications and provides long lasting improvement of dysphagia.
Our group designed a progressive approach to endoscopic balloon dilation based on
tailoring certain technical aspects of the dilation process.
Most studies in the literature concluded that endoscopic dilation is safe and
effective in relieving dysphagia caused by benign esophageal strictures of various
etiologies. There have been few studies that investigated the optimal target of endoscopic
dilation of benign esophageal strictures.
Our main retrospective secondary study, 27 patients underwent balloon dilation for
benign esophageal stricture. Etiology of the esophageal stricture (n=27) included, peptic
(n=18, 66.7%), anastomotic (n=4, 14.8%) eosinophilic esophagitis (n=3, 11.1%), post
Heller myotomy (n=1, 3.7%) and radiation induced (n=1, 3.7). The diameter of the
esophageal stricture ranged from 6mm to 12mm with the most common diameter being
9mm (15%) or 10mm (26%). Most balloon dilations started at 15mm (range 12-15mm,
n=26, 59.2%) or >15mm (n=11, 40.7%) with end dilation of <15mm (n=4, 14.8%), 15<18mm (n=7, 25.9%), 18-20mm (n=16, 59.3%). Most patients had 1 to 3 dilations at an
interval of every 2-4 weeks to achieve goal diameter of 16-8mm. Many patients with follow
up data (77%), all had clinical improvement of their dysphagia.
Our study sheds light on the possibility that our novel progressive approach
improves the patient’s dysphagia without causing complications, although further
investigation is warranted in the form of a prospective randomized trial. Although
endoscopic esophageal dilation is considered the best initial therapeutic approach for
benign esophageal strictures, the best technique to perform the procedure remains to be
determined.
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CHAPTER 1. INTRODUCTION
1.1 Introduction
Benign esophageal strictures are a frequently encountered problem in clinical
practice. Patients with an esophageal stricture typically have dysphagia (difficulty
swallowing) to solids and sometimes liquids too. The goal of endoscopic intervention for
patients with benign esophageal strictures is relief of dysphagia by disrupting the stricture
hence, increasing the diameter of the esophageal lumen by dilation. Dilation is
accomplished by application of expansible forces (inflation pressure and dilation force)
against the luminal stenosis. No clear advantage of either balloon or mechanical dilation
(tapered solid dilation) has been demonstrated but the choice of which to use is provider
dependent. Treatment of esophageal strictures with dilation is a relatively safe and effective
procedure that has been done for decades.
1.2 Conservative Endoscopic Dilation Approach
For decades, the ‘‘rule of three’’ has been accepted and applied to mechanical
dilator (tapered solid dilation) use for esophageal strictures. This conservative approach to
dilation was designed to reduce the risk of complications such as bleeding or perforation.
The starting point and degree of dilation within a session is based on the severity of the
stricture. Specifically, the initial dilator chosen is based on the known or estimated stricture
diameter followed by serial increases in dilator diameter. After moderate resistance is
encountered with the mechanical type of dilator, no greater than three consecutive dilators
in increments of 1 mm should be passed in a single session. However, following this rule
increases the number of endoscopic dilations required and the health care-related costs (1).
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This rule does not apply to balloon dilators, studies have suggested that inflation of
a single large diameter dilator (>15 mm) or incremental dilation of greater than 3 mm is
safe in simple esophageal strictures (2). Obviously, perforation remains the concern,
although balloon dilation provides real-time, direct visualization of the mechanistic effects
of the dilation and allows more aggressive but safe dilation. Although more expensive,
balloon dilation seems to result in safe management of more complicated and tighter
strictures with fewer sessions and a lower recurrence rate (2). Most providers perform a
balloon dilation to a desired lumen diameter and only perform another interval dilation
procedure if dysphagia recurs in the future. Most endoscopists are trained to dilate up to a
satisfactory luminal diameter based on their discretion once either resistance is felt, or an
adequate therapeutic mucosal tear or excessive bleeding is endoscopically visualized.
1.3 Evolution of Endoscopic Dilation
The management of benign esophageal strictures have slowly evolved over the
decades based on “expert opinion.” For instance, the “rule of three” in dilation of
esophageal strictures suggests that in a single session, no more than three bougie dilators
of sequentially larger size should be passed once moderate or greater resistance is evident
(1). Unfortunately, no meaningful guideline exists to help providers achieve long-lasting
dilation free periods of benign esophageal strictures. How much dilation can be achieved
in a single endoscopic session of dilation, and what luminal diameter should be the end
point remains controversial. There is no data on the optimal duration over which the
balloon is inflated. Most would agree that gaining 1 to 2 mm of luminal diameter with three
consecutive passes of dilators of increasing size during one session is a good general rule.
Most patient experience complete relief of dysphagia when a luminal diameter of >15mm
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is achieved. There have been a few recent studies that touch on a single aspect of the
balloon dilation technique such as inflation time, interval between balloon dilation
sessions, or optimal balloon dilator size. Each of the studies demonstrated an improvement
in dysphagia or achieved a durable esophageal lumen after dilation. With our progressive
endoscopic approach, we alter not just one but a few technical aspects of the balloon
dilation technique process to determine if a larger esophageal lumen diameter of the
stricture can be achieved, resulting in better clinical outcomes. Even though our two
retrospective studies are not definitive, it does raise the potential that an algorithm for
effective balloon dilation of benign esophageal stricture can be achieved with considerable
results.
1.4. Progressive Endoscopic Dilation Approach
At our tertiary medical center, we changed a couple of technical aspects of the
conservative balloon dilation technique to determine if this would result in a more efficient
and safe approach for benign esophageal stricture management. The progressive approach
involves gradual inflation of balloon diameter over 3 minutes from the smallest to largest
balloon diameter size of that catheter. Depending on the degree of narrowing of the
esophageal stricture, the initial balloon diameter chosen was 12mm with the goal of
eventually achieving >=16-20mm dilation. Consecutive dilation procedures were
scheduled within 2-3 weeks until a target diameter of at >= 16 mm was achieved regardless
of symptomatic relief of their dysphagia. At the next endoscopic procedure, the balloon
diameter used will be the next size up based on previous session. For example, in the first
session a 12-13.5-15mm balloon diameter was used, second session we will use a 15-1618mm balloon diameter and third session an 18-19-20mm balloon diameter will be used.
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1.5 Critical Evaluation of Our Approach
The main concern with our progressive endoscopic dilation approach is if it
increases the rate of complications especially perforation or hemorrhage due to our goal of
achieving a lumen diameter of >16mm in as few dilations as possible. According to the
medical literature there has not been a correlation established between size of balloon
dilation and rate of perforation or hemorrhage. The consensus during fellowship training
and in medical practice is to not aggressively dilate too much more than the starting
diameter of the esophageal stricture. Usually when we observe a tear in the mucosal layer
of the stricture after dilation, we tend to stop further dilation due to the fear of perforation
or hemorrhage, but this may not be the case. With our progressive dilation approach, a
gradual stepwise dilation over 3 minutes allows a controlled dilation without excessive
balloon inflation force. The key is to follow the simple tenet “start low and go slow” when
performing dilation. We routinely inspect the esophageal lumen mucosa by direct
visualization through the balloon after every 1-2mm dilation increments or after
encountering resistance.
The other concern is performing a consecutive dilation 2-3 weeks later may accrue
excessive healthcare costs and putting the patient through unnecessary endoscopic
procedures. Our goal is to start with a 12mm diameter balloon dilator, progress slowly with
a repeat dilation session every 2-3 weeks, with the goal of achieving a diameter of 16 to 18
mm. For simple esophageal strictures this can be achieved during the initial endoscopic
session, whereas complex or tight strictures may require an average of 2 to 5 endoscopic
sessions. By performing another dilation of the stricture at short intervals (every 2-3 weeks)
prior to the patient either complaining of recurrent dysphagia or restenosis of the stricture,
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may provide a longer lasting effect. We believe this provides longer relief of dysphagia
and maintenance of the esophageal lumen prior to recurrent fibrosis of the stricture.
1.6 Significance of Our Research
Even though the conservative endoscopic management of strictures is a safe and
effective method for benign esophageal strictures and relief of dysphagia, there may be a
better way. The current treatment modality of choice in benign esophageal strictures is
endoscopic dilatation, although the best technique for dilatation and type of stricture
amenable to treatment is controversial. A variety of endoscopic therapies are available to
treat these strictures, although even in the current era there are relatively few prospective
and/or randomized studies available to compare different techniques and clinical outcomes,
and most of the available literature is based on retrospective data.
Despite vast amounts of data about the theory of how to dilate, unfortunately there
is no consensus on a systematic and safe approach that is efficient, limits complications
and provides long lasting improvement of dysphagia. Little is known about optimal size of
the balloon dilation and inﬂation time. There is also no consensus regarding how frequent
the interval of balloon dilations should be performed. Our study sheds light on the
possibility that our novel progressive approach may improve the patient’s dysphagia
without causing complications, although further investigation is warranted. This study will
build onto the current medical knowledge and lead to significantly better endoscopic
management of benign esophageal strictures in the field of gastroenterology.
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CHAPTER 2. BACKGROUND
2.1 Background
A benign esophageal stricture is an often-encountered problem in gastroenterology,
characterized by a narrowing of the esophageal lumen causing dysphagia to solid food
and/or liquids. Other symptoms of esophageal stricture include regurgitation or aspiration,
chest or epigastric abdominal pain, or weight loss. The formation of benign esophageal
strictures is caused by the production of fibrous tissue and deposition of collagen stimulated
by chronic inflammation (3-4). The most common causes of benign esophageal strictures
are listed in Table 1. These include peptic strictures due to uncontrolled gastroesophageal
reflux disease (GERD), anastomotic (post-surgical), radiation induced, ingestion of a
caustic substance, or eosinophilic esophagitis (3, 5-6).
2.2 Etiologies of Benign Esophageal Strictures (see Table 1)
Peptic included strictures account for up to 80% of all benign esophageal strictures
(7). Peptic injury results from the chronic exposure of the esophagus to gastric acid
contents. Fortunately, there has been a decrease in the incidence of peptic strictures due to
the widespread use of proton pump inhibitors (PPI’s) which help regulate excessive gastric
acid production. Schatzki rings are benign, fibrous rings that are commonly found in the
lower esophagus and are strongly associated with the presence of a hiatal hernia (8).
Caustic strictures are most commonly due to the ingestion of concentrated alkali solutions
(lye). Eosinophilic esophagitis is becoming a more frequently encountered cause of benign
esophageal strictures. This entity is common in young patients with otherwise unexplained
dysphagia that presents with food bolus impaction. Eosinophilic esophagitis is an
inflammatory disease of the esophagus due to the infiltration of eosinophils into the
mucosal layer. Esophageal strictures are present in 30% to 80% of adults with eosinophilic
6

esophagitis. Anastomotic strictures can occur after esophagectomy for esophageal cancer
resection or other esophageal surgery such as repair of esophageal perforations or thoracic
trauma. Anastomotic strictures usually result from ischemia or excessive fibrosis of the
anastomosis (esophagogastric) (9).
2.3 Classification of Benign Esophageal Strictures
Benign esophageal strictures are categorized into two types: simple and complex
(10). Simple esophageal strictures are short (1-2 cm long), focal, and with a diameter
>12mm that allows the passage of the upper endoscopy that has diameter of 9-10mm (1014). These strictures include Schatzki rings, esophageal webs, and peptic strictures. Simple
esophageal strictures typically tolerate large increments of dilation at one session. Complex
benign esophageal strictures are usually long (>2 cm), asymmetric, angulated, and severely
narrowed or inability to pass the upper endoscope (10-15). Typically, one to three dilations
achieve relief of dysphagia in simple strictures. Complex strictures are more difficult to
treat and tend to be refractory or to recur despite dilation therapy (10-15).
The cause of recurrent and refractory benign esophageal strictures is thought to be
a result of intense fibrogenesis during healing and after the dilation-induced trauma. The
underlying pathogenesis varies depending on the distinct types of strictures. For example,
peptic strictures develop because of ulceration and inflammation caused by
gastroesophageal reflux, while anastomotic strictures are formed because of relative
ischemia at the site of anastomosis. The most common etiologies of recurrent and
refractory strictures include anastomotic strictures, caustic strictures, and radiation-induced
strictures. Caustic injuries and radiation induced strictures have more involvement of
deeper layers of the esophageal wall, such as the muscularis propria, that makes a stricture
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more complex to treat and increase the risk for perforation (16). Strictures compromising
only a superficial esophageal layer such as esophageal webs, Schatzki ring and peptic
strictures, respond better to dilation.
According to medical literature a recurrent or refractory stricture usually results
from luminal narrowing from scarring or fibrosis in the absence of inflammation. A benign
inflammatory esophageal stricture is not considered in the definition since the stricture is
unlikely to improve until the inflammation subsides or is treated appropriately. The benign
esophageal stricture is labeled refractory when unable to successfully dilation the anatomic
problem to a diameter of 14 mm over five sessions at 2-week intervals (4,13). The benign
esophageal stricture is recurrent when unable to keep a satisfactory luminal diameter for 4
weeks once the target diameter of 14 mm has been achieved (4,13). When strictures are
refractory or recurrent, dilation therapy combined with steroid injections, incisional
therapy, metal esophageal stent placement, or surgery may need to be considered (17). To
prevent stricture recurrence, the injection of steroids into the stricture site following
endoscopic dilation has been reported to prevent stricture recurrence (15-21). The
mechanism of action has been suggested to be the local inhibition of the inflammatory
response, resulting in a reduction of collagen formation (17-23).
2.4 Method and Types of Dilators
The method of esophageal dilation varies depending on the type of dilator used and
how it is performed. Dilation is either done with a balloon or mechanical dilator (Maloney
or Savary dilators) that are passed through the esophagus with or without the use of a
guidewire and with or without the aid of fluoroscopy. The mechanistic action by which the
esophageal stricture is dilated also depends on the type of dilator used. Balloon dilators
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dilate the stricture lumen by distributing the dilating force radially and simultaneously
across the entire length of the stricture. Mechanical dilators deliver both a radial and a
longitudinal force across the entire length of the stricture.
Balloon dilators can be passed through-the-scope (TTS) with or without a
guidewire depending on the complexity of the stricture. Through-the-scope balloon dilators
are designed to pass through the working channel of the upper endoscope with or without
wire guidance so that dilatation can be seen. The balloon is made of low-compliance,
inflatable, thermoplastic polymers that allow uniform and reproducible expansion to the
specified diameter (17). Most balloons allow for sequential expansion to multiple
diameters. The balloon size needs to be carefully matched to the size of the stricture.
Dilating balloons are expanded by pressure injection of liquid using either water or radioopaque contrast using a handheld accessory device. Inflation with radio-opaque contrast
allows for fluoroscopic visualization. The hydraulic pressure of the balloon is monitored
manometrically to gauge the radial expansion force.
The guidewire balloon dilation approach is used when the stricture lumen diameter
is too narrow for the endoscope to pass through or when the stricture is long or angulated.
In general, complex strictures typically require the use of a guidewire for mechanical
dilators or direct visualization with a balloon dilator either endoscopically or under
fluoroscopic guidance (24). The balloon dilator should be positioned so that the narrowest
part of the stricture is at the center of the balloon. Multistage diameter balloon catheters
enable the application of a multistep radial dilation force by gradually increasing the
inflation pressure. The dilators are typically inﬂated with water (or radio-opaque material
if performed under ﬂuoroscopy) to pressures that correspond to speciﬁc dilation diameters.
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The dilation force can is affected by factors such as the inflation pressure, balloon diameter,
and severity of stricture (24). An adequate dilation force at the stricture is important in
achieving a therapeutic mucosal tear of the stricture, but excessive dilation force can result
in adverse events such as perforation.
As mentioned, mechanical dilators include either Maloney dilators that are mercury
or tungsten filled bougies passed without the aid of a guidewire or Savary dilators that are
wire guided polyvinyl dilators. The Maloney type bougies have a tapered tip and can be
passed either blindly or under fluoroscopic control. This type of dilator is used for simple
strictures with a diameter of 12-14 mm. The risk of esophageal perforation is higher due to
the blind passage of Maloney dilators especially in patients with a large hiatal hernia, a
tortuous esophagus, or complex strictures (25-26). The Savary dilators are polyvinyl
chloride, cylindrical solid tubes with a central channel to accommodate the guidewire.
They are the most widely used ranging from 5-20 mm diameter. Savary dilators are passed
over a guidewire that has been positioned with the tip in the gastric antrum with or without
fluoroscopic guidance.
2.5 Technical Aspects of Endoscopic Dilation
The extent of dilation to achieve a certain luminal diameter during a single
endoscopic session is still controversial. When using mechanical dilators, the rule of three
is applied by dilating at least 1 to 2 mm of luminal diameter dilation with through three
consecutive passes of dilators of increasing size during one session. This rule of three is
applied to help prevent adverse events such as excessive bleeding or perforation.
Depending on the type of stricture, balloon dilators may allow even more increase in
luminal diameter to be achieved during a session. The main benefit of balloon dilation is
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the direct endoscopic visualization of the stricture during dilation that allows more
aggressive but safe dilation.
Patients usually require repeated endoscopies to reach a satisfactory luminal
diameter. However, the best target diameter of endoscopic dilation of benign esophageal
strictures is unknown and therefore an arbitrary measure. When a luminal diameter of 1315 mm is achieved, most patients can tolerate a regular diet. But to ensure luminal patency,
patients are usually dilated to 16–20 mm. The question is whether the additional
millimeters past the 16 mm are effective. The degree of dilation within a session should be
based on the severity of the stricture by estimating the stricture diameter, followed by serial
increases in the diameter of the dilating balloon (9). One to three dilations are needed to
relieve dysphagia due to simple strictures, with only 25-35% of patients requiring repeated
dilation (12). There is no data on the best duration the balloon should remain inﬂated, but
national and international guidelines recommend inﬂation times from 30 to 60 seconds (910).
2.6 Potential Complications of Dilation
The most common procedural complications with any type of dilator include
perforation, bleeding, infection, or aspiration. The most serious complication of esophageal
dilation is perforation. Perforation risk varies between 0.1% and 0.4% (27). The risk of
perforation is higher in complex strictures compared to simple strictures (28-29). Radiation
induced strictures tend to have severe and highest risk of perforation. Perforation after
esophageal dilation usually occurs at the site of the stricture (intrathoracic or
intraabdominal part of esophagus). This complication should be suspected if severe or
persistent chest pain, dyspnea, tachycardia, or fever occurs. A chest radiograph may show
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free air from a perforation. Although a normal chest radiograph does not entirely rule out
this possibility. Therefore, a water-soluble contrast esophagogram or contrast chest
computed tomogram may be necessary (30). In a few select cases, a fully covered metal
esophageal stent is effective management of perforations after dilation of benign or
malignant esophageal strictures (31-32). Mild bleeding after effective dilation is common
and due to mucosal disruption caused by dilation. Rate of significant hemorrhage after
dilation has been reported to be 0.4% (33).
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CHAPTER 3. REVIEW OF THE LITERATURE
3.1 Safety and Effectiveness of Dilation for Esophageal Strictures
In a study by Drabek J et al. that looked at the effectiveness and complication rate
of balloon dilation for management of benign esophageal strictures. Twenty-two patients
were diagnosed as having benign esophageal stricture. All patients except two showed
immediate improvement: 59% were cured; 18% had at least one recurrence of the stenosis;
9% had improvement but treatment continues; 14% needed other treatment (34). They had
two major complications for perforation. They concluded that balloon dilatation was an
effective and safe method for treatment of the benign esophageal strictures.
Polese et al, conducted a retrospective study on 95 patients treated by endoscopic
dilation (Savary or through the scope (TTS) balloon dilation) without fluoroscopic
guidance for benign esophageal strictures. The etiologies were: anastomotic (n=38), postfundoplication (n=13), caustic (n=14), peptic (n=11), radiation-induced (n=10) and others
(n=9) (35). A total of 472 dilation sessions were conducted without any serious
complications. Recurrence of dysphagia was found in 33% and 51% of the patients after 2
months and 1 year, respectively. Improvement of dysphagia, the number of sessions, and
recurrence were significantly better in the patients with postsurgical stenosis as compared
with those affected by caustic, peptic, and radiation-induced strictures.
Mendelson et al. performed a retrospective study of 74 patients with an anastomotic
esophageal stricture after esophagectomy that had been dilated over a 5-year period (564
dilations; median follow-up period, 8 months) (36). Patients were dilated with either TTS
balloon dilator (57%), Savary dilators (8%) or both (35%). Of the 74 patients, 93% had
initial relief of dysphagia. The stricture recurred in 43% of patients, and 69% were
13

considered refractory (36). There were no major complications in this study. The
prevalence of an esophageal stricture after esophagectomy ranges from 9%-48% (37).
These benign strictures may develop because of collagen deposition and fibrin production
from deep ulceration or chronic inflammation (12, 33). They found that endoscopic dilation
was successful in achieving luminal patency, but anastomotic strictures often recur and are
refractory.
Pereira-Lima et al, performed 1043 dilation sessions on 153 patients using SavaryGilliard dilators or Eder-Puestow dilators (12). Dilation sessions were done on a weekly
basis until a lumen size of 14-15mm was obtained. Dilation was repeated whenever
dysphagia recurred. Stricture etiologies were postsurgical in 80 patients, peptic in 37,
caustic in 12, and from other causes in 11 patients. The median maximum diameter of the
inserted dilators was 14mm. The median number of sessions required for achieving
adequate dilation, together with relief of dysphagia during the follow-up, among patients
with peptic stenosis was 3, in comparison to 5 in patients with either caustic or anastomotic
strictures. Absence of dysphagia was accomplished in 66.5% of the patients at the end of
follow-up. They concluded that endoscopic dilation is safe and effective in relieving
dysphagia caused by benign esophageal strictures of varied etiologies, although frequent
repeated sessions are necessary due to stricture recurrence.
3.2 Optimal Dilation Diameter
The optimal target of endoscopic dilation of postsurgical esophageal strictures is
unknown. Helsema et al, conducted a retrospective study to compare the dilation-free
period of patients with benign anastomotic stricture after esophagectomy who underwent
balloon or bougie dilation up to 16 mm with patients who were dilated up to 17 or 18 mm.
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Eighty-eight patients were dilated up to the largest diameter of 16 mm and 91 patients to a
diameter >16 mm. The stricture recurrence rate was 79.5 % in the 16 mm group and 68.1
% in the >16 mm group (38). The overall dilation-free period had a median of 41.5 days
and 92 days, respectively. They concluded that endoscopic dilation over 16 mm resulted in
a signiﬁcant prolongation of the dilation-free period in comparison with dilation up to 16
mm in patients with benign anastomotic strictures after esophagectomy. This study
concluded that endoscopic dilation over 16 mm resulted in a significant prolongation of
the dilation-free period in comparison with dilation up to 16 mm in patients with benign
anastomotic strictures after esophagectomy.
Another important question is whether dilation to 16 mm or more is safe and does
not increase the risk of esophageal perforation. In the study by Helsema et al, only one of
the eight perforations occurred after dilation of 16 mm or more. The overall perforation
rate reported in the literature after endoscopic dilation of benign esophageal strictures,
varies from 0 to 1.8% (38). Other studies using balloon dilation deemed that dilation over
3 mm per session was safe and feasible. In a study by Park et al. reported that 89% of
patients with anastomotic strictures were dilated to maximum balloon size of 20 mm during
the initial dilation session with no major complications. (37). In another retrospective study
by Yoda et al, balloon dilation sizes of 12-15mm and 15-18 mm diameter were used in
patients with severe (<5 mm diameter) and moderate (5-10 mm diameter) strictures,
respectively (39). This study reported a perforation rate of 0.3%. A retrospective study by
Kim et al, that included patients with esophagojejunal anastomotic strictures with median
diameter of 5-6 mm, reported that 66% of their patients were dilated up to 16.5–20mm in
one or two sessions, which the occurrence of only one perforation (40). Despite these
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studies being conducted in patients with anastomotic esophageal strictures, it does support
our goal dilation point of >16mm during the first one to two endoscopic sessions.
Vermeulen et al, performed endoscopic balloon dilation in 751 patients with benign
esophageal strictures. The retrospective study aimed to show risk factors for refractory
benign esophageal strictures and assess long term clinical outcomes of endoscopic dilation
(41). They figured out that endoscopic dilation up to 13 to 15 mm was associated with a
higher number of endoscopic dilations sessions than dilation up to 16 to 18 mm.
Furthermore, more than 60% of patients with benign esophageal strictures remained free
of endoscopic dilation after 1 year of follow-up. Compared with peptic strictures,
anastomotic, radiation and caustic strictures were associated with a higher number of
endoscopic dilation sessions.
The findings from these studies and others have several implications for clinical
practice. First, they demonstrated that dilation up to 16 to 18 mm was associated with less
future endoscopic dilations which suggested that endoscopists should consider dilating to
at least 16 mm in benign esophageal strictures. These studies also show that noncompliance
with the rule of 3 was not associated with esophageal perforation. Further confirming that
dilation over 3 mm per session can be safely performed without an increased risk of
esophageal perforation (42).
3.3 Balloon Inflation Time
Wallner et al. evaluated the best balloon dilator inflation time for benign esophageal
strictures. Even though there are no national or international guidelines, recommended
inflation times range from 20 to 60 seconds (43). The aim of their pilot study was to
compare the efficacy of 10 seconds balloon dilation inflation time with 2 minutes inflation
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time. Dilation was made using a TTS balloon, with 15-18mm or 18-20-mm diameter.
Twenty patients with symptomatic strictures were prospectively studied in a randomized
fashion. Of the 20 patients evaluated, the 10-second group required an average of 1.4
dilations per patient; the 2-minute group required an average of 1.5 dilations per patient
(15). This pilot study concluded that 10 seconds inflation time was as effective as 2
minutes. Although balloon dilatation is the primary treatment for benign dysphagia,
information about the optimal inflation time is lacking. Unfortunately, this pilot study only
looked at a two inflation times instead of a range of different inflation times to truly
determine a difference. Even though this study investigates an important aspect of balloon
dilation it was not descriptive on patient demographics such as etiologies or how the
balloon dilation was performed.
Wang et al conducted a study to evaluate the inflation duration of endoscopic
dilation for benign esophageal strictures after esophageal surgery or endoscopic
submucosal dissection. The clinical effects and adverse events were compared among the
three groups, 1, 3 and 5 minutes for inflation time of balloon dilation. There was a total of
57 patients, including 21 in the 1-min group, 18 in the 3-min group and 18 in the 5-min
group, were included. The stricture recurrence rate was 76.19% in the 1-min group, 55.56%
in the 3-min group and 61.11% in the 5-min group (44). The dysphagia-free periods were
comparable between the 3- and 5-min groups but were longer than those in the 1-min group.
When the dilation duration was longer than 3 min, muscle layer damage occurred in two
patients in the 5-min group and in no patients in the other two groups, which indicated that
prolonged dilation could destroy the esophageal tissue structure (44). Three minutes was
considered a safe and effective dilation duration for benign esophageal strictures after
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esophageal surgery or endoscopic submucosal dissection. This study supports our balloon
inflation duration of 3 minutes for the progressive endoscopic approach.
3.4 Subsequent Balloon Dilation Interval
In a study by Buyukkarabacak et al. that aimed to evaluate their 16 patients who
underwent multiple dilations with the diagnosis of resistant benign esophageal stricture.
All patients underwent dilatation with Savary-Gilliard bougie dilators. Following the first
dilation performed for dysphagia, 7 patients underwent endoscopy and dilatation 3 to 5
times within 1-week intervals without waiting for the development of dysphagia
symptoms. They found that dilatations performed at frequent intervals without waiting for
the symptoms of dysphagia can contribute to safer and more effective results in resistant
benign esophageal strictures (45). Even though Savary-Gilliard bougie dilators were used
instead of balloon dilators, most studies have not shown much difference between the
effectiveness of either type of dilator. This study supports our notion that performing a
repeat dilation at a shorter interval before the patient complaints of recurrent dysphagia or
restenosis of the stricture, may provide longer lasting relief.
3.5 Factors Affecting Dilation Force in Balloon Dilation
Nishikawa et al. conducted a performed an experiment using phantom models to
investigate the relationships between inflation pressure, balloon size, and radial dilation
force (46). The balloon dilation procedure was performed for each stricture model using
three sizes of balloon: 10-11-12 mm, 12-13.5-15 mm, and 15-16.5-18 mm. Each balloon
catheter was placed in the 5-mm stricture model and inflated to the three stages of pressure
(2, 4, and 6 atm) for each balloon diameter. Their aim was to determine which balloon size
should be selected to achieve a specific target diameter.
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There was a positive association between inflation pressure and dilation force was
observed for each balloon size. The dilation force increased as the inflation pressure
increased for all three sizes of balloons assessed. A greater dilation force was applied for
larger than for smaller balloons at the same inflation pressure. They compared the dilation
force when multiple sizes of balloon were inflated to a certain diameter (12 and 15 mm).
When balloons were inflated to the same diameter, the smaller balloon generated
significantly greater dilation force than the larger one. When targeting the maximum
dilation (15 mm) of a 12-13.5-15 mm balloon and minimum dilation (15 mm) of a 15-16.518 mm balloon using the same 5-mm stricture size, the dilation force was higher in the 1213.5-15 mm balloon compared with the 15-16.5-18 mm balloon. This is probably because
a smaller balloon requires more inflation pressure to achieve the same diameter. Using the
same stricture size, the dilation force was significantly higher when applying the maximum
size of a smaller balloon compared with a larger balloon. An inverse association between
stricture size and dilation force was observed in the 12-13.5-15 mm. They also performed
other experiments using 3-mm and 7-mm strictures and obtained equivalent results. They
compared the dilation force using stricture models of different severity, and we found that
the larger dilation force occurred with severe strictures. To perform safe and effective
esophageal balloon dilation, the inflation pressure and balloon size should be selected after
considering the stricture size and target diameter (46).
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CHAPTER 4. RETROSPECTIVE STUDIES
4.1 Specific Aims
Aim 1) To determine if our progressive endoscopic balloon dilation approach will
result in better clinical outcomes, defined as symptomatic improvement and less
recurrence of dysphagia based on follow up data. Hypothesis: Our progressive
endoscopic approach will have significantly better clinical outcomes in terms of
symptomatic improvement and less recurrence of dysphagia in patients with benign
esophageal strictures.
Aim 2) To evaluate the technical success of our progressive endoscopic approach, in
terms of less return visits for repeat endoscopic procedures due to achieving a lumen
diameter of at least 16mm. Hypothesis: The progressive approach will be a more
technically successful procedure due to less endoscopic procedures to achieve a goal lumen
diameter of at least 16mm.
Aim 3) To determine the rate of postoperative procedural related complications, such
as bleeding, infection, perforation with the progressive endoscopic approach in the
management of benign esophageal strictures. Hypothesis: The progressive endoscopic
approach will be associated with fewer postoperative procedural related complications.
4.2 Materials and Methods
Our studies were retrospective, single center, cohort study and were approved by
the IRB of University of Kentucky. We performed an electronic search through our
endoscopic database and medical records to find patients who underwent upper
gastrointestinal endoscopy with dilation therapy for benign esophageal strictures between
January 2012 and December 2017 for preliminary study and January 2012 and November
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2021 for our secondary study. We excluded any endoscopic balloon dilation performed by
another provider besides Dr. Houssam Mardini, since is the only provider that utilizes the
progressive balloon dilation approach. We included adult patients (18-99 years old) who
received endoscopic balloon dilation by Dr. Houssam Mardini for a benign esophageal
stricture. Strict confidentiality and patient’s privacy protection was kept throughout the
entire data collection process. At the time of the endoscopic procedure, the details of the
procedure were explained to the patient and an informed consent was signed.
Other inclusion criteria included patients presenting with dysphagia (difficulty
swallowing) due to a benign esophageal stricture due to any of the following etiologies:
peptic (sequela of reﬂux esophagitis), radiation inducted, caustic ingestion, anastomotic
stricture (post-surgical), and eosinophilic esophagitis-associated stricture. Exclusion
criteria included patients less than 18 years of age, malignant esophageal stricture, stricture
found in the gastrointestinal tract other than the esophagus, diagnosis of achalasia and if
the patient was pregnant.
4.3 Data Collection
We retrospectively collected the baseline variables from the electronic medical
records that are presented in Table 2 and 3. The following variables were also included in
the data collection: the number of endoscopies needed to reach the target diameter; largest
luminal diameter reached; number of balloon dilations performed and dilation related
complications. The stricture diameter was estimated by the endoscopist and based on the
size the dilator at which mild resistance was felt during balloon dilation. To decide the
location of the stricture, the esophagus was divided into three segments: proximal (<25 cm
from the incisors), mid (25–30 cm from the incisors) and distal (>30 cm from the incisors).
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4.4 Pre/post operative and Endoscopic Procedure Detail
Although the endoscopic procedures in this study were not standardized because of
the retrospective nature of this study, we give a description of how endoscopic dilation was
usually performed at our institution. Endoscopic dilation was performed as an outpatient
procedure. Patients were asked to fast for at least 6 hours prior to the procedure.
Anticoagulants were stopped 2–5 days before the procedure depending on the type of
anticoagulant. No routine antibiotic coverage was required. During the informed consent
process, patients were informed about any potentials complications from anesthesia or the
procedure such as the risk of perforation, bleeding or infection and the possible need for
surgery should perforation occur. Patients received either monitor anesthesia care (MAC)
sedation using propofol under the supervision of an anesthesia team or conscious sedation
using midazolam and/or fentanyl administered by the endoscopist Dr. Houssam Mardini.
Depending on the degree of narrowing of the esophageal stricture, the initial
diameter (mm) size of the balloon dilator was chosen with the goal of eventually achieving
>=16mm dilation. Patients were dilated up to a satisfactory luminal diameter based on the
discretion of the endoscopist once either resistance was met, or an adequate therapeutic
mucosal tear was endoscopically visualized. Patients were discharged 1–2 hours after the
intervention after tolerating liquid diet under the supervision of the nursing staff and
endoscopist. Any consecutive dilation procedures were scheduled within 2-3 weeks until a
target diameter of at >= 16 mm was achieved. The final target diameter was an arbitrary
measure that mainly depended on the preference of the endoscopist performing the
procedure but maintaining safety measures to prevent procedural complications. The
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patient was then discharged and instructed to contact the outpatient clinic in case of
recurrent dysphagia.
4.5 Statistical Analysis
All results were expressed as mean or percentage. Descriptive statistics such as
means, and percentages were used for continuous and categorical data.
4.6 Preliminary Study Results
During the study period, 19 patients who underwent balloon dilation with a
diagnosis of benign esophageal stricture were retrospectively reviewed (Table 2). Of these
19 patients, the mean age of 64 (range 27-86 years) and 58% (n=11) males. The etiology
of the esophageal stricture was peptic induced (n=14, 73.6%), anastomotic (n=1, 5.3%)
eosinophilic esophagitis (n=3, 15.8%), and radiation induced (n=1, 5.3%). The location of
the esophageal stricture included, proximal (n=3, 16%), mid (n=4, 21.1%), distal (n=11,
57.9%), and both proximal/distal (n=1, 5%). All the endoscopic procedures with balloon
dilation were performed by the same endoscopist (Dr. Houssam Mardini). The balloon
dilation was performed over the course of at least 3 minutes or more. Most common
diameter (mm) of the esophageal was 9mm (25%) and 10mm (17.8%). Largest balloon
dilation used for esophageal stricture 12mm (n=2, 10.5%), 15mm (n=5, 26.3%), 16.5mm
(n=1, 5.26%), 18mm (n=7, 36.8%), and 20mm (n=3, 15.7%). The number of balloon
dilations done per patient with esophageal stricture include, one (n=9, 47.3%), two (n=5,
26.3%), and three or more (n=5, 26.3%). Most of the balloon dilation in the rest of patients
were routinely repeated between 2-4 weeks. Nine of the 10 patients that we have follow up
data on had clinical improvement in their symptoms of dysphagia. Of the 1 that did not
have clinical improvement, he had a radiation induced stricture which are typically
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refractory strictures. Technical success of the procedure was achieved 100% and no
complications occurred in any patient. This study shows that our progressive approach
achieves symptomatic improvement without an increase in complications, although further
investigation is called for.
4.7 Secondary Study Results
During the study period, 27 patients underwent balloon dilation with a diagnosis of
benign esophageal stricture. (Table 3). Of these 27 patients, the mean age of 58 (range 2286 years) and 52% (n=14) males. Etiology of the esophageal stricture (n=27) included,
peptic (n=18, 66.7%), anastomotic (n=4, 14.8%) eosinophilic esophagitis (n=3, 11.1%),
post Heller myotomy (n=1, 3.7%) and radiation induced (n=1, 3.7%). Location of
the esophageal stricture included, proximal (n=3, 11.1%), mid (n=4, 14.8%), and distal
(n=20, 74.1%). All the endoscopic procedures with balloon dilation were performed by the
same endoscopist (Dr. Houssam Mardini). The balloon dilation was performed over the
course of at least 3 minutes or more. The diameter of the esophageal stricture ranged from
6mm to 12mm with the most common diameter being 9mm (15%) or 10mm (26%). Most
balloon dilations started at 15mm (range 12-15mm, n=26, 59.2%) or >15mm (n=11,
40.7%) with end dilation of <15mm (n=4, 14.8%), 15-<18mm (n=7, 25.9%), 18-20mm
(n=16, 59.3%) (Table 4). Our goal for dilation lumen diameter was 16-18mm. The number
of balloon dilations done per patient were usually 1 to 3 times depending on the severity
of the stricture. The patients routinely had a balloon dilation performed every 2-4 weeks.
Most patients with follow up data (77%), all had clinical improvement of their dysphagia.
There was one patient that did not report clinical improvement of dysphagia. On further
investigation, she had a severe 6mm diameter peptic stricture. No complications occurred
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in any patient. Technical success of the procedure was achieved in all patients throughout
all the procedure done.
This study helps confirm that our novel progressive endoscopic balloon dilation
approach may lessen the number of endoscopic procedures but also improve dysphagia
without an increased risk of procedural complications. Hopefully, our research will
stimulate interest in performing further research studies to investigate the role each
technical aspects of endoscopic balloon dilation has on benign esophageal strictures.
Changing a certain aspect of how the esophageal stricture is dilated may result in better
patient outcomes.
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CHAPTER 5. DIFFICULTIES IN THE RESEARCH
5.1 Study Limitations
There are limitations to these studies. First, the sample size was small, and the study
was retrospective in design at a single tertiary medical center. A larger prospective and
randomized controlled trial is needed to further confirm our results. We would suggest
conducting these future research studies at a few tertiary medical centers to inform patient
recruitment and decrease bias. These factors introduce bias and decrease the study’s
statistical strength. However, both our retrospective studies demonstrated that balloon
dilation for benign esophageal stricture with our proposed technique had a considerable
symptomatic improvement in their dysphagia and improvement in the lumen size of the
stricture. Even though a goal dilation of at least 16 mm or more was achieved in most
patients it is difficult to determine the long-term dilation-free period due to gaps in the data
available and limited long term follow up. Most studies seem to stop at 15-16mm lumen
diameter, but some studies suggest that increasing the target diameter of endoscopic
dilation up to 18-20mm may be more effective.
5.2 Research Difficulties
The original plan for the research study was to be a double-blind, randomized
prospective clinical trial of comparative effectiveness of two balloon dilation methods
(standard vs. progressive approach) for benign esophageal strictures. We planned to recruit
a total of patients 40 that would be randomized using blocks of 8 or 10 to have half of the
participants (n = 20) that would have the standard approach of balloon dilation and the
other half (n = 20) would have the progressive approach to balloon dilation. This type of
research plan would have limited the issues we faced with our retrospective study.
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We had originally plan to start the prospective study at the end of 2019 with a few
patients that were enrolled but unfortunately the COVID-19 pandemic became a huge
obstacle for patient recruitment, enrollment, and performance of elective or non-emergent
endoscopic procedures. There were supposed to be other endoscopists that participated in
the research study, but they had left the University of Kentucky gastroenterology division
prior to or during the time that the study was conducted. Another issue we encountered was
that I finished my gastroenterology fellowship at University of Kentucky on June 30, 2018,
then went to Maine Medical Center to complete my advanced endoscopy fellowship by
June 30, 2019. Afterwards, I accepted a full-time position as a gastroenterologist/advanced
endoscopist with Gastroenterology Associates, P.C. in Casper, Wyoming. Due to my
absence from the University of Kentucky, I was not able to physically be involved with
patient recruitment, enrollment, or data collection process. We had to rely on other students
and research personnel to assist with the progress of the study and collect the retrospective
data.
Due to the many obstacles, we encountered, the research study was converted into
a retrospective study with focus on patients that had underwent our proposed progressive
endoscopic dilation approach for benign esophageal strictures by Dr. Houssam Mardini.
Converting the research study to retrospective made the data collection and analysis part
easier but of course with any retrospective study there is bias, gaps in the data collection
and limited statistical strength to make definitive conclusions from the results.
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CHAPTER 6: CONCLUSIONS AND FUTURE RECOMMENDATIONS
6.1 Discussion
Typically, most endoscopists follow a standard approach to balloon dilation for
benign esophageal strictures. This involves a gradual balloon dilation where the balloon is
inflated to each inflation pressure (atm) to achieve a particular balloon diameter until the
largest balloon diameter is reached. The initial dilator size chosen approximates the
diameter of the stricture for the dilator or may be slightly larger. Each balloon dilator
diameter is usually held for 30-60 seconds then inflated to the next largest balloon diameter
size of the balloon catheter. When using a mechanical dilator, the “rule of three” is followed
to achieve an adequate dilator of the stricture without any complications such as excessive
bleeding or perforation. When using a balloon dilator, the stopping point of dilation is quite
arbitrary based on the experience of the endoscopist. For instance, the endoscopist may
choose to stop as soon as there is a therapeutic mucosal tear or excessive bleeding on
endoscopic examination. Others may choose to stop dilation at a certain diameter of the
balloon regardless. In the standard approach, a repeat balloon dilation is done when the
patient has recurrence of dysphagia. In clinical practice, how balloon dilation is performed
is vast based on endoscopist preference rather than data driven. This begs the question that
there should be a more standardized and data driven approach to balloon dilation of benign
esophageal stricture that if efficient, effective, and safe.
Our progressive approach involves a gradual non-stop inflation of balloon diameter
over or more 3 minutes from the smallest to largest balloon diameter size of that balloon
catheter. The initial balloon diameter size is 12mm, regardless of the size of the stricture
size. The goal is to achieve 16-18mm or more luminal diameter after the dilation session.
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By performing a gradual balloon dilation, we can achieve an adequate luminal diameter
safely without the dreaded complication of perforation. The procedure is then repeated
every 2-3 weeks depending on the final lumen diameter achieved despite if symptomatic
relief occurred after the first dilation. By achieving a larger enough lumen diameter of >1618mm, we believe that patients will have a higher chance of symptomatic relief (dysphagia)
and decrease the rate of stricture recurrence.
Despite vast amounts of data on the technicality of how to dilate, unfortunately
there is no consensus on a systematic and safe approach to limit complications and result
in long term symptomatic improvement. There is also no consensus on how frequent the
interval of balloon dilations should be performed. It is well established that balloon or
mechanical dilation is an effective and safe approach to benign esophageal stricture. A few
preliminary studies have been conducted in recent years that shed light on specific aspects
of our progressive approach to balloon dilation for esophageal strictures. The study by
Nishikawa et al demonstrated the interacting factors that inflation pressure, dilation force
and diameter of the stricture play in the end results of the stricture. By tailoring one or more
of these technical aspects, we can develop a more standardized approach that is not only
effective and safe but able to achieve long term relief of dysphagia with less need to repeat
endoscopic procedures in the future.
6.2 Conclusions
Our retrospective study demonstrated that balloon dilation for benign esophageal
stricture with our proposed technique had a considerable symptomatic improvement in
their dysphagia and improvement in the lumen size of the stricture. Dilation of least 16 mm
or more resulted in a significant prolongation of the dilation-free period. Most studies seem
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to stop at 15-16mm lumen diameter but increasing the target diameter of endoscopic
dilation up to 18-20mm may be more effective.
Our study sheds light on the possibility that our novel progressive approach
improves the patient’s dysphagia without causing complications, although further
investigation is warranted in the form of a prospective randomized trial. This study will
build onto the current medical knowledge and lead to significantly better endoscopic
management for benign esophageal strictures. With our cavalier approach to dilating
benign esophageal strictures more aggressively but safely we discard the rule of three and
do a more standardized technique that is individualized to the type of esophageal stricture
and patients’ needs.
In conclusion, this study demonstrates the following: 1) endoscopic dilation can
achieve luminal remediation with a high degree of technical success and a low
complication rate; 2) strictures require frequent dilation at short intervals especially due to
etiologies with a high recurrence rate such as anastomotic, radiation or caustic strictures.
Although endoscopic esophageal dilation is considered the best initial therapeutic approach
for benign esophageal strictures, the best technique to perform the procedure remains to be
determined.
6.3 Future Recommendations
Due to the retrospective nature of the study, we can only make assumptions of the
results, but future investigation should validate the results of our studies with a double blind
prospective randomized design. In this study, we demonstrated that progressive approach
to endoscopic dilation of benign esophageal strictures to a target diameter of more than
16mm every 2-3 weeks as needed seemed to result in resolution of the dysphagia without
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an increased risk of complications. However, due to the limited data available and patients
without long term follow up we cannot determine if the progressive approach was
associated with a long-term dilation-free period.
Future research should focus on simple or complex strictures with well-constructed
studies comparing various aspects of the progressive approach to balloon dilation modality
to identify ideal treatment algorithms. Most of the research studies in the literature either
focus on benign esophageal strictures in general or on one etiology, commonly radiation
induced or anastomotic stricture. Since peptic induced strictures are the most common
cause of benign esophageal strictures encountered by gastroenterologist, I suggest focused
study on this etiology using the progressive endoscopic dilation approach. There can also
be focused studies on caustic, radiation induced, eosinophilic esophagitis or anastomotic
structures, given their recurrent and refractory tendency. Each etiology of benign strictures
responds differently and therefore, each such be investigated separately using the
progressive endoscopic approach. Although dysphagia caused by peptic esophageal
strictures tend to be milder and easier to manage in the short term, recurrent strictures
necessitating repeat endoscopic dilatation is a significant problem in the long term due to
the chronic nature of gastroesophageal reflux disease (47). Future research should
investigate the response of recurrent or refractory strictures with our progressive
endoscopic approach.
However, the cost-effectiveness of dilation to >16 mm and the maximum increase
in diameter during a single session of endoscopic dilation might be the subject of future
research. Besides a potential benefit in cost-effectiveness, more effective treatment of
benign esophageal strictures may also affect the quality of life. Every esophageal stricture
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has its own characteristics and difficulties therefore, some individualized variation in
technique may be needed for successful therapy.
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APPENDIX
Table 1.1: Common Etiologies of Benign
Esophageal Strictures
Peptic (reflux induced)
Schatzki’s ring
Eosinophilic Esophagitis
Radiation induced
Anastomotic (Post-surgical - Esophagus)
Caustic Ingestion
Photodynamic Therapy

Table 2.1: Demographic and Clinical Characteristics of Preliminary
Study Patients
Variable
Age, mean, (range)
Male
Female
Etiology:
Peptic
Anastomotic
Eosinophilic Esophagitis
Radiation
Location in esophagus
Upper
Mid
Distal
Upper and Distal
Stricture Diameter (mm)
6mm
>6mm-9mm
>9-10mm

No. (%)
64 (27-86)
11 (58%)
8 (42%)

14 (73.6%)
1 (5.3%)
3 (15.8%)
1 (2.3%)
3 (15.8%)
4 (21.1%)
11 (57.9%)
1 (5%)
1 (5.2%)
10 (53%)
8 (42%)
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Table 3.1: Demographic and Clinical Characteristics of Secondary Study
Patients
Variable
Age, mean, (range)
Male
Female
Etiology:
Peptic
Anastomotic
Eosinophilic Esophagitis
Radiation
Post Heller myotomy
Location in esophagus
Upper
Mid
Distal
Stricture Diameter (mm)
6mm
>6mm-9mm
>9-10mm

No. (%)
58 (22-86)
14 (51.9%)
13 (48.1%)
18 (66.7%)
4 (14.8%)
3 (11.1%)
1 (3.7%)
1 (3.7%)
3 (11.1%)
4 (14.8%)
20 (74.1%)
3 (11.1%)
13 (48.1%)
11 (40.7%)

Table 3.2
: Endoscopic Balloon Dilation Characteristics of Secondary Study
No. (%)
Variable
Starting Treatment Dilation size (mm)
<15mm
15mm
>15mm

End Treatment Dilation Size (mm)- Last
session
<15mm
15-<18mm
18mm
Number of Balloon Dilation(s) - End of Therapy
1 Dilation
2 Dilations
3 Dilations
>3 Dilations
Clinical Success (Dysphagia Resolved)
n=22 with follow up data
n= 5 unknown (no follow up data)
Yes
No
Procedural Complications
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5 (18.5%)
11 (40.7%)
11 (40.7%)

4 (14.8%)
7 (25.9%)
9 (33.3%)
10 (37%)
9 (33%)
4 (15%)
4 (15%)

21 (95%)
1 (4.5%)
None
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